Science
2020 Was a Breakout Year for Crispr – WIRED
Between glimpses of a medical cure and winning science’s shiniest prize, this proved to the gene-editing technology’s biggest year yet.
The pandemic sped up the need for such tests. This summer, the FDA authorized two Crispr-based tests, both for detecting SARS-CoV-2. Boston-based Sherlock Biosciences received the green light for its test in May, and the Bay Areas Mammoth Biosciences followed in August. It marked the first time the FDA has allowed a Crispr-based diagnostic tool to be used on patients. The tests still need to be analyzed in a lab, but they are faster than the standard method for detecting SARS-CoV-2, called PCR,…
Continue Reading